<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is considered as a major health problem, as its prevalence continuously rises worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>One of the common health consequences of <z:hpo ids='HP_0001513'>obesity</z:hpo> is type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, antiobesity management is a prerequisite in treating diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>Lifestyle modifications combined with pharmacological agents appear to be an effective approach </plain></SENT>
<SENT sid="4" pm="."><plain>Sibutramine is a <z:chebi fb="19" ids="28790">serotonin</z:chebi>-<z:chebi fb="15" ids="33569">noradrenaline</z:chebi> reuptake inhibitor, which acts centrally by promoting the feeling of satiety and decreasing caloric intake, thus resulting in <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>A potential association with cardiovascular side effects has been noted </plain></SENT>
<SENT sid="6" pm="."><plain>Orlistat, a gastric and pancreatic lipase inhibitor, also achieves significant <z:hpo ids='HP_0001824'>weight loss</z:hpo> and improves glycaemic status, but it has gastrointestinal side effects </plain></SENT>
<SENT sid="7" pm="."><plain>Rimonabant, the first endocannabinoid CB1 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, is associated with weight reduction and it improves diabetic parameters; nevertheless, it is associated with <z:hpo ids='HP_0000708'>psychiatric disorders</z:hpo>; indeed, a recently conducted safety review led to the temporal suspension of its commercialization </plain></SENT>
<SENT sid="8" pm="."><plain>The above-mentioned medications seem to be currently useful agents for treating <z:hpo ids='HP_0001513'>obesity</z:hpo> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Other medications used for <z:mp ids='MP_0002055'>diabetes</z:mp> management, such as exenatide, liraglutide and pramlintide, have also shown body weight reduction </plain></SENT>
<SENT sid="10" pm="."><plain>Ongoing research is needed to scrutinize the precise impact of these agents in the daily clinical practice of management of <z:hpo ids='HP_0001513'>obesity</z:hpo> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>